---
title: "Olanzapine - Schizophrenia"
sidebar: mydoc_sidebar
permalink: db00334-mesh-d012559-1.html
toc: false 
---


Path ID: `DB00334_MESH_D012559_1`
{% include image.html url="images/db00334-mesh-d012559-1.png" file="db00334-mesh-d012559-1.png" alt="db00334-mesh-d012559-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| DB:DB00334 | Olanzapine | Drug |
| UniProt:P14416 | Dopamine D2 receptor | Protein |
| GO:0061527 | Dopamine secretion, neurotransmission | BiologicalProcess |
| UBERON:0000451 | Prefrontal complex | GrossAnatomicalStructure |
| HP:0000708 | Behavioral abnormality | PhenotypicFeature |
| MESH:D012559 | Schizophrenia | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Olanzapine | DECREASES ACTIVITY OF | Dopamine D2 Receptor |
| Dopamine D2 Receptor | INCREASES ABUNDANCE OF | Dopamine Secretion, Neurotransmission |
| Dopamine Secretion, Neurotransmission | LOCATED IN | Prefrontal Complex |
| Prefrontal Complex | POSITIVELY REGULATES | Behavioral Abnormality |
| Behavioral Abnormality | MANIFESTATION OF | Schizophrenia |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB00334#mechanismofaction](https://go.drugbank.com/drugs/DB00334#mechanismofaction)
  - [https://psychopharmacologyinstitute.com/publication/mechanism-of-action-and-pharmacodynamics-of-olanzapine-2161](https://psychopharmacologyinstitute.com/publication/mechanism-of-action-and-pharmacodynamics-of-olanzapine-2161)
